Roche Pharmaceutical Development and Sales Overview

Xolair Global sales CHFbn CER growth +10% Regional sales CER growth 1.8 1.6 1.4 1.2 US +10% 1.0 0.8 0.6 0.4 0.2 0.0 YTD Sep 19 YTD Sep 20 YTD Sep 21 YTD Sep 22 YTD Sep 2022 sales of CHF 1,625m • US: Xolair remains market leader in growing biologics asthma market; Growth driven by chronic spontaneous urticaria (CSU) CER-Constant Exchange Rates Roche 158

View entire presentation